Elios Vision Acquisition by Bausch + Lomb

Healthcare M&A activity in the first quarter of 2024 showed steady growth, with 29 transactions compared to 28 in the previous year. The biopharma sector led the way, accounting for 45% of deal volume, while services lagged behind, although significant transactions like Novo Holdings’ acquisition of Catalent showcased some activity. Looking ahead, we anticipate continued strong M&A activity in the biopharma space as major pharmaceutical companies seek to boost their revenue and pipelines through acquisitions of late-stage or commercial-stage companies. Pre-commercial biopharma companies are also likely to explore various strategic options, including mergers, private company mergers, and cash-out transactions, given the dynamic nature of capital markets.